# US 2021/0171509 A1 · Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171509 A1
- Document ID: US20210171509A1
- Status: Published application
- Kind: A1
- Application number: 17/097,314
- Filed: 2020-11-13
- Published: 2021-06-10
- Earliest claimed: 2019-11-14
- Assignees: Foresee Pharmaceuticals Co., Ltd.
- Applicants: Foresee Pharmaceuticals Co., Ltd.
- Inventors: Wenjin YANG; Kai-Wei CHANG
- Web page: https://patentgrep.com/patent/US20210171509A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61K 31/4427: containing further heterocyclic ring systems
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C12Y 304/24065: Macrophage elastase (3.4.24.65), i.e. metalloelastase
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

## Claims

### Claim 1

A compound of formula (I):
or a tautomer, stereoisomer, pharmaceutically acceptable salt, or hydrate thereof,
wherein:
ring A is an optionally substituted heteroaryl;
Q is CR2 or N;
R1 is hydrogen or alkyl;
each R2 is independently hydrogen, alkyl, halo, hydroxyl, haloalkyl, alkoxy, alkylthio, amino, amido, alkylamino, aminoalkyl, cyano, hydroxyalkyl, —(CH2)pC(O)OR6, or —(CH2)pOC(O)R6;
R3 is hydrogen, halo, or alkyl;
each R4 and R5 is independently hydrogen or alkyl;
each R6 is independently hydrogen or alkyl, wherein the alkyl is unsubstituted or substituted with one or more groups independently selected from amino, hydroxyl, halo, and alkoxy;
X is S or O;
Y is:
n is 1, 2, 3 or 4; and
p is 0, 1, 2, 3, 4, or 5.

### Claim 2 (depends on 1)

The compound of claim 1, wherein ring A is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 heteroatoms independently selected from O, S and N, wherein the 5- to 6-membered monocyclic heteroaryl is optionally substituted with alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein ring A is pyridinyl, furanyl, thienyl, or N-methyl pyrazolyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein ring A is:

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen or C1-4 alkyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n is 1 and R2 is —CH3.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen.

### Claim 8 (depends on 1)

The compound of claim 1, wherein each of R4 and R5 is hydrogen.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X is S.

### Claim 10 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Q is N.

### Claim 12 (depends on 1)

The compound of claim 1, wherein Y is:

### Claim 13 (depends on 1)

The compound of claim 1, wherein Y is:

### Claim 14 (depends on 1)

The compound of claim 1, wherein:

### Claim 15 (depends on 1)

The compound of claim 1, wherein:
ring A is pyridinyl, furanyl, thienyl, or N-methyl pyrazolyl;
R1 is hydrogen, —CH3 or —CH2CH3;
R2 is —CH3, —C(O)NH2, —CH2OH, —OCH3, or —OH;
each of R3, R4, and R5 is hydrogen;
X is S or O;
Y is
Q is CH or N; and
n is 1.

### Claim 16

A compound selected from the group consisting of:
or a tautomer, stereoisomer, pharmaceutically acceptable salt, or hydrate thereof.

### Claim 17 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, and at least one pharmaceutically acceptable carrier.

### Claim 19 (depends on 18)

A method of inhibiting macrophage elastase (MMP-12) in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 18.

### Claim 20 (depends on 18)

A method of treating a disease mediated by macrophage elastase (MMP-12) in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 18, wherein the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), a emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

### Claim 21

(canceled)
